Value of monoclonal anti-myeloperoxidase (MPO7) for diagnosing acute leukaemia

J Storr, G Dolan, E Coustan-Smith, D Barnett, J T Reilly

Abstract

The expression of myeloperoxidase (MPO) was studied in 100 cases of acute leukaemia (83 with acute myeloid leukaemia (AML) and 17 acute lymphoblastic leukaemia (ALL)) by both a conventional cytochemical method and the immunocytochemical antiperoxidase (APAAP) technique using the monoclonal antibody MPO7. In each case the staining was evaluated by light microscopic examination (percentage of positive cells). Of the 83 cases of AML, 78 (93.9%) were positive for MPO7 compared with 70 (84.3%) by cytochemistry. Antibodies against the myeloid markers CD13 and CD33 were positive in 71 (85.5%) and 70 (84.3%) cases, respectively. Importantly, all cases of ALL were negative for both MPO7 and cytochemical MPO staining even when they were positive for CD13 and CD33. These results indicate that the antmyeloperoxidase antibody MPO7 is the most sensitive and specific reagent for the diagnosis of AML and should therefore be included in routine immunophenotyping panels.

Accurate classification of acute leukaemia, particularly the distinction between acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), has important clinical consequences. The usefulness of immunophenotyping is well known in the diagnosis of ALL. Cytology and cytochemistry are mostly used in the classification of AML, and form the basis of classification in the French-American-British (FAB) system.

The main limitations of monoclonal antibodies against myeloid antigens are that they may react with only a proportion of cases, and some have been shown to lack specificity for AML.

Myeloperoxidase (MPO) is a lysosomal enzyme found in the primary granules of cells of the myeloid series. The expression of MPO occurs early in myeloid differentiation and seems to be specific for cells of this lineage. Importantly, MPO has never been reported in ALL even in those rare cases expressing MPO mRNA.

Conventional cytochemistry is widely used for the demonstration of "active" enzyme in leukaemic cells, but very low concentrations of MPO antigen can now be detected using monoclonal antibodies and the alkaline phosphatase-antialkaline phosphatase (APAAP) technique.

This study compares the sensitivity and specificity of monoclonal anti-MPO (MPO7) with that of other monoclonal antibodies as well as with conventional cytochemical staining.

Methods

Peripheral blood and bone marrow samples were obtained from patients with acute leukaemia. A haematological diagnosis was based on Romanowsky staining, cytochemistry, and immunophenotyping. The panel of monoclonal antibodies against surface antigens included CD13, CD33 (Coulter/Seralab) CD14, CD19, anti-HLA-DR and CD7 (Becton-Dickinson/Royal Free Hospital). Analysis was performed by flow cytometry (Pacsan, Becton-Dickinson), and the data analysed using a Consort 30 program. Cytoplasmic CD3 (Becton-Dickinson/Seralab), CD22 and U (Sera lab), and TdT (Dakopatts A/S) expression were assessed by indirect immunofluorescence. Samples were regarded as positive if an antigen was expressed by more than 10% of cells.

MPO was assessed in each case using two techniques, a standard cytochemical technique using the Hanker-Yates method and an alkaline phosphatase anti-alkaline phosphatase APAAP technique, using the monoclonal antibody MPO7 (obtained from Dakopatts A/S). Samples were regarded as positive if more than 3% of blasts stained with cytochemical MPO or greater than 10% with MPO7.

Cases of AML were subdivided according to the FAB classification and results of cytochemical and immunocytochemical investigations compared.

Results

The 100 cases of acute leukaemia were classified as AML (n = 83) and ALL (n = 17) by standard FAB criteria. Of the cases of AML, 78 (93.8%) were positive for MPO7 compared with 70 (84.3%) for cytochemistry. Antibodies against the myeloid antigens CD13 and CD33 were positive in 71 (85.5%) and 70 (84.3%) of cases, respectively. The percentage of leukaemic cells reacting with MPO7, CD13, CD33 and cytochemical MPO for each FAB group are shown in fig 1.

Five (6%) cases of AML were negative for MPO7 while 13 (15.6%) cases were negative.
by the cytochemical MPO method; 12 (14.4%) and 13 (15.6%) cases were negative for CD13 and CD33, respectively. All cases negative for MPO7 were also negative by cytochemistry. Of the four cases of M5 from this group, two were positive for both CD13 and CD33, while the remaining two were positive for only one antigen. These four cases, however, were positive for the monocytoid determinant CD14. The M6 case negative for MPO7 was positive for both CD13 and CD33. Cases failing to react with MPO7 seemed to be mainly confined to the M5 subtype while those cases negative for cytochemical MPO, CD13, and CD33 were independent of subtype (fig 1).

Results of immunological and cytochemical techniques for myeloperoxidase detection are shown in fig 2. While both are relatively simple, the percentage cell positivity was consistently greater using MPO7 (fig 3). Interestingly, Auer rods were less easily shown by MPO7 than by cytochemistry, probably...
because they were obscured by the denser staining achieved with this technique. All 17 cases of ALL were negative with MPO7 and cytochemical MPO while 10 and eight cases exhibited CD13 and CD33 positivity, respectively. Six cases were positive for both CD13 and CD33.

Discussion
The accurate diagnosis of AML is important for appropriate treatment and management. Morphology and cytochemistry are not sufficiently precise to enable all cases of AML to be distinguished from those of ALL. MPO detection is probably the most specific technique for differentiating myeloid from lymphoid lineages. Our results show that MPO7 is the most sensitive method for distinguishing AML, with only 60% of cases negative. Of these, four were subtyped as M5 on the basis of the activity with anti-CD14, and one as M6 by glycoporphin positivity. Therefore, the combined use of only two antibodies—namely, MPO7 and CD14—successfully characterised 99% of cases of AML. Importantly, all cases belonging to subgroup M1 reacted positively with MPO7. This is important as these cases are the most difficult to differentiate from ALL, not only on morphological grounds, but also because they most frequently coexpress lymphoid antigens. Cytochemistry and standard myeloid antibodies were less sensitive in the diagnosis of M1, with six (23%) negative by cytochemistry, nine (39%) negative using anti-CD13, and three (13%) negative with anti-CD33. The discrepancy between immunological and cytochemical MPO detection is probably due to the presence of an antigenically intact but non-functioning enzymes, such as proMPO, in these cells. This has been reported to occur in the myeloblastic cell line KG-1.

All cases of ALL were negative for myeloperoxidase both by MPO7 and cytochemistry, confirming the enzyme specificity, though this observation was based on a relatively small number of cases and should be confirmed using larger numbers. This degree of specificity was not found with other "myeloid" antibodies as, for example, over half the cases of ALL reacted with anti-CD13. The greater incidence of "lineage promiscuity" in this study, compared with that reported previously, may reflect the small number of cases of ALL studied and the fact that both centres receive a disproportionate number of diagnostically difficult cases. It is not explained by our definition of positivity as the results are not significantly changed if this is increased from 10% to 20% or greater.

These results confirm those of a recently published study which used an indirect immunofluorescence technique and an inhouse anti-MPO. We suggest, therefore, that MPO7, in conjunction with the APAAP technique, which permits individual cell identification, is more sensitive than alternative anti-myeloid antibodies and standard cytochemistry.

This work was supported in part by the Haematology Research Fund (Northern General Hospital). We also thank Dakopatts A/S for their help with this project. We are also indebted to Dr D Campana for helpful discussion and advice.

Value of monoclonal anti-myeloperoxidase (MPO7) for diagnosing acute leukaemia.

J Storr, G Dolan, E Coustan-Smith, D Barnett and J T Reilly

*J Clin Pathol* 1990 43: 847-849
doi: 10.1136/jcp.43.10.847

Updated information and services can be found at:
http://jcp.bmj.com/content/43/10/847

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/